News | May 05, 2022
JBCPL emerges as the fastest growing pharma company: Report
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Demand for pharmacies contribute to 52% of the total searches, vaccination centres 30%
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
The plant is expected to start commercial operations from Q4FY24
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Subscribe To Our Newsletter & Stay Updated
